Literature DB >> 12821951

Cost of poor blood pressure control in the UK: 62,000 unnecessary deaths per year.

F J He1, G A MacGregor.   

Abstract

High blood pressure is the most important risk factor for cardiovascular disease. With the information on systolic blood pressure from the recently published meta-analysis of prospective studies, we calculated the reductions in stroke and ischaemic heart disease with control of all hypertensives to a systolic blood pressure of 140 mmHg. For adults there would be a reduction of 28-44% in stroke and 20-35% in ischaemic heart disease depending on age. In the UK, this would prevent approximately 21,400 stroke deaths and 41,400 ischaemic heart disease deaths each year. Around half of those who suffer a stroke or ischaemic heart disease survive, there would be a proportionate decrease in these people as well. These amount to approximately 42,800 strokes and 82,800 ischaemic heart diseases saved, making a total of 125,600 events saved a year in the UK. This would result in a reduction in disability and major cost savings both to individuals, their families and the Health Service. The blood pressure levels and control of blood pressure in many countries are similar to those in the UK, so the reductions in stroke and ischaemic heart disease worldwide, if the same control of high blood pressure could be obtained, would be immense.

Entities:  

Mesh:

Year:  2003        PMID: 12821951     DOI: 10.1038/sj.jhh.1001581

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  22 in total

1.  Hypertension and lifestyle modification: how useful are the guidelines?

Authors:  Rachel Nicoll; Michael Y Henein
Journal:  Br J Gen Pract       Date:  2010-12       Impact factor: 5.386

2.  Under pressure.

Authors:  George I Varughese; Abd A Tahrani
Journal:  Br J Gen Pract       Date:  2006-08       Impact factor: 5.386

3.  Physical health indicators in major mental illness: analysis of QOF data across UK general practice.

Authors:  Julie Langan Martin; Richard Lowrie; Alex McConnachie; Gary McLean; Frances Mair; Stewart W Mercer; Daniel J Smith
Journal:  Br J Gen Pract       Date:  2014-10       Impact factor: 5.386

Review 4.  Epigenome mapping in normal and disease States.

Authors:  Alika K Maunakea; Iouri Chepelev; Keji Zhao
Journal:  Circ Res       Date:  2010-08-06       Impact factor: 17.367

5.  Construction of shRNA targeted to the rat angiotensin II type 1 receptors and its RNAi in cytoplasma.

Authors:  Chuanshi Xiao; Ling Qiu; Qiutang Zen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 6.  Therapeutic RNA-silencing oligonucleotides in metabolic diseases.

Authors:  Algera Goga; Markus Stoffel
Journal:  Nat Rev Drug Discov       Date:  2022-02-24       Impact factor: 84.694

7.  Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension.

Authors:  Irina Bogdarina; Simon Welham; Peter J King; Shamus P Burns; Adrian J L Clark
Journal:  Circ Res       Date:  2007-01-25       Impact factor: 17.367

8.  Therapeutic inertia and the Medicare crisis.

Authors:  Thomas G Pickering
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-09       Impact factor: 3.738

9.  Blood pressure measurement in atrial fibrillation: goodbye mercury?

Authors:  T Watson; G Y H Lip
Journal:  J Hum Hypertens       Date:  2006-04-13       Impact factor: 3.012

Review 10.  Prehypertension is not associated with all-cause mortality: a systematic review and meta-analysis of prospective studies.

Authors:  Xiaofan Guo; Xiaoyu Zhang; Liqiang Zheng; Liang Guo; Zhao Li; Shasha Yu; Hongmei Yang; Xinghu Zhou; Lu Zou; Xingang Zhang; Zhaoqing Sun; Jue Li; Yingxian Sun
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.